| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL18R Beta |
| Uniprot No | O95256 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-356aa |
| 氨基酸序列 | FNISGCSTKKLLWTYSTRSEEEFVLFCDLPEPQKSHFCHRNRLSPKQVPE HLPFMGSNDLSDVQWYQQPSNGDPLEDIRKSYPHIIQDKCTLHFLTPGVN NSGSYICRPKMIKSPYDVACCVKMILEVKPQTNASCEYSASHKQDLLLGS TGSISCPSLSCQSDAQSPAVTWYKNGKLLSVERSNRIVVDEVYDYHQGTY VCDYTQSDTVSSWTVRAVVQVRTIVGDTKLKPDILDPVEDTLEVELGKPL TISCKARFGFERVFNPVIKWYIKDSDLEWEVSVPEAKSIKSTLKDEIIER NIILEKVTQRDLRRKFVCFVQNSIGNTTQSVQLKEKRVDHHHHHH |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-18R Beta重组蛋白的模拟参考文献示例，结合其结构、功能及应用的典型研究方向：
1. **文献名称**：*"Cloning and Functional Characterization of Recombinant Human IL-18 Receptor Beta"*
**作者**：Hoshino, K., et al.
**摘要**：该研究成功克隆并在哺乳动物细胞中表达了重组人IL-18R Beta蛋白，证实其与IL-18的高亲和力结合，并揭示其在NF-κB信号通路激活中的关键作用，为后续炎症机制研究奠定基础。
2. **文献名称**：*"Structural Insights into IL-18 Signaling via Recombinant IL-18R Beta Complex"*
**作者**：Boraschi, D., et al.
**摘要**：通过X射线晶体学解析重组IL-18R Beta与IL-18的复合物结构，阐明受体-配体互作的关键结构域，为设计靶向IL-18通路的抑制剂提供理论依据。
3. **文献名称**：*"Recombinant IL-18R Beta Modulates T Cell Responses in Autoimmune Disease Models"*
**作者**：Nakanishi, K., et al.
**摘要**：研究发现，外源性重组IL-18R Beta蛋白可竞争性抑制IL-18介导的Th1细胞分化，显著减轻小鼠实验性结肠炎症状，提示其作为潜在免疫调节剂的治疗价值。
4. **文献名称**：*"Expression Optimization and Bioactivity Analysis of IL-18R Beta in Prokaryotic Systems"*
**作者**：Kim, S.H., et al.
**摘要**：优化大肠杆菌表达系统生产重组IL-18R Beta的工艺，通过体外实验验证其阻断IL-18诱导的IFN-γ产生能力，为大规模制备功能性受体蛋白提供技术参考。
*注：上述文献为模拟内容，实际研究中建议通过PubMed或Google Scholar检索真实发表论文。*
Interleukin-18 receptor beta (IL18Rβ), also known as IL-1 receptor-like 2 (IL1RL2) or IL-18R1. is a key component of the IL-18 signaling complex. As a member of the interleukin-1 receptor (IL-1R) family, it plays a critical role in mediating inflammatory and immune responses. Structurally, IL18Rβ is a type I transmembrane protein composed of an extracellular immunoglobulin (Ig) domain, a transmembrane region, and a cytoplasmic Toll/IL-1 receptor (TIR) domain. It functions as a co-receptor alongside IL18Rα (IL-18R1), forming a heterodimeric complex that binds the pro-inflammatory cytokine IL-18 with high affinity. This interaction triggers downstream signaling pathways, including NF-κB and MAPK activation, leading to the production of inflammatory mediators like IFN-γ.
IL18Rβ is expressed on immune cells such as T cells, NK cells, and macrophages. Its signaling pathway is implicated in both innate and adaptive immunity, influencing Th1 cell differentiation, antiviral defenses, and autoimmune disorders. Dysregulation of IL-18/IL18Rβ signaling has been associated with chronic inflammatory diseases (e.g., rheumatoid arthritis, Crohn's disease), allergic conditions, and cancer progression.
Recombinant IL18Rβ proteins are engineered for research and therapeutic development. Produced typically in mammalian expression systems, these purified proteins retain functional domains to study ligand-receptor interactions, screen inhibitors, or develop decoy receptors. In therapeutic contexts, blocking IL18Rβ signaling has emerged as a strategy to mitigate excessive inflammation in autoimmune diseases. As research continues, IL18Rβ remains a focal point for understanding immune regulation and designing targeted immunotherapies.
×
